Abstract
This study determined the optimal maintenance dose of omeprazole in reflux oesophagitis. One hundred and ninety three patients rendered asymptomatic and healed after four or eight weeks omeprazole were randomised double blind to 10 mg omeprazole once daily (n = 60 evaluable), 20 mg omeprazole once daily (n = 68), or placebo (n = 62) for one year or until symptomatic relapse. Each omeprazole regimen was superior to placebo in preventing both symptomatic relapse (life table analysis, p < 0.001) and endoscopically verified relapse (p < 0.001). At 12 months, the life table endoscopic remission rates (proportions of patients without grade > or = 2 oesophagitis) were: 50% (95% confidence intervals 34 to 66%) with 10 mg omeprazole once daily, 74% (62 to 86%) with 20 mg omeprazole once daily, and 14% (2 to 26%) with placebo. At 12 months, the life table symptomatic remission rates (proportions of patients asymptomatic or with mild symptoms) were: 77% (64 to 89%) with 10 mg omeprazole once daily, 83% (73 to 93%) with 20 mg omeprazole once daily, and 34% (16 to 52%) with placebo. Both 10 mg and 20 mg omeprazole once daily were effective in prolonging the remission of reflux oesophagitis: 10 mg may be appropriate to start longterm treatment, though the existence of a dose response relation means that 20 mg once daily may be effective in patients for whom 10 mg once daily is suboptimal.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bate C. M., Booth S. N., Crowe J. P., Hepworth-Jones B., Taylor M. D., Richardson P. D. Does 40 mg omeprazole daily offer additional benefit over 20 mg daily in patients requiring more than 4 weeks of treatment for symptomatic reflux oesophagitis? Aliment Pharmacol Ther. 1993 Oct;7(5):501–507. doi: 10.1111/j.1365-2036.1993.tb00125.x. [DOI] [PubMed] [Google Scholar]
- Bate C. M., Richardson P. D. Clinical and economic factors in the selection of drugs for gastroesophageal reflux disease. Pharmacoeconomics. 1993 Feb;3(2):94–99. doi: 10.2165/00019053-199303020-00002. [DOI] [PubMed] [Google Scholar]
- Dent J. Australian clinical trials of omeprazole in the management of reflux oesophagitis. Digestion. 1990;47 (Suppl 1):69–71. doi: 10.1159/000200521. [DOI] [PubMed] [Google Scholar]
- Gore S., Healey C. J., Sutton R., Eyre-Brook I. A., Gear M. W., Shepherd N. A., Wilkinson S. P. Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther. 1993 Dec;7(6):623–628. doi: 10.1111/j.1365-2036.1993.tb00143.x. [DOI] [PubMed] [Google Scholar]
- Hemery P., Galmiche J. P., Roze C., Isal J. P., Bruley des Varannes S., Lavignolle A., Le Bodic L. Low dose omeprazole effects on gastric acid secretion in normal man. Gastroenterol Clin Biol. 1987 Feb;11(2):148–153. [PubMed] [Google Scholar]
- Lundell L., Backman L., Ekström P., Enander L. K., Falkmer S., Fausa O., Grimelius L., Havu N., Lind T., Lönroth H. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol. 1991 Mar;26(3):248–256. doi: 10.3109/00365529109025038. [DOI] [PubMed] [Google Scholar]
- Savarino V., Mela G. S., Zentilin P., Cutela P., Mele M. R., Vigneri S., Celle G. Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. Dig Dis Sci. 1994 Jan;39(1):161–168. doi: 10.1007/BF02090077. [DOI] [PubMed] [Google Scholar]
- Sharma B. K., Walt R. P., Pounder R. E., Gomes M. D., Wood E. C., Logan L. H. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut. 1984 Sep;25(9):957–964. doi: 10.1136/gut.25.9.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Smith P. M., Kerr G. D., Cockel R., Ross B. A., Bate C. M., Brown P., Dronfield M. W., Green J. R., Hislop W. S., Theodossi A. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology. 1994 Nov;107(5):1312–1318. doi: 10.1016/0016-5085(94)90532-0. [DOI] [PubMed] [Google Scholar]